Breaking News
Eye Drop Proven to Slow Myopia Progression in Children

The findings from a recent clinical trial indicate that a potential breakthrough drug therapy, aimed at slowing down the advancement of nearsightedness in children, may be within reach.

Eye Drop Proven to Slow Myopia Progression in Children
June 02, 2023
Revolutionary Gene Therapy Restores Sight to Child with LCA

In a remarkable medical breakthrough, two retinologist surgeons at the Maisonneuve-Rosemont Hospital ophthalmology clinic have successfully performed groundbreaking gene therapy on an 11-year-old boy.

Revolutionary Gene Therapy Restores Sight to Child with LCA
May 30, 2023
FTC Files Lawsuit to Block Amgen's Acquisition of Horizon Therapeutics

The US Federal Trade Commission has filed a lawsuit with the intention of preventing Amgen's $27.8 billion acquisition of Horizon Therapeutics.

FTC Files Lawsuit to Block Amgen's Acquisition of Horizon Therapeutics
May 23, 2023
Contact Lens Brands with Forever Chemicals Revealed: Alcon, Acuvue, Coopervision

A recent report from Mamavation has revealed that eighteen different types of soft contact lenses, including three major brands—Alcon, Acuvue, and Coopervision—contain detectable levels of organic fluorine.

Contact Lens Brands with Forever Chemicals Revealed: Alcon, Acuvue, Coopervision
May 23, 2023
Update: Contaminated Eye Drops Lead to Another Death, More Cases of Vision Loss

The US Centers for Disease Control and Prevention (CDC) has provided an update on the ongoing situation involving infections caused by contaminated eye drops.

Update: Contaminated Eye Drops Lead to Another Death, More Cases of Vision Loss
May 22, 2023
FDA Approves Bausch + Lomb and Novaliq's Miebo for Dry Eye Treatment

Bausch + Lomb announced that the FDA has granted approval for Miebo (perfluorohexyloctane ophthalmic solution; previously referred to as NOV03) to treat the signs and symptoms of dry eye disease (DED).

FDA Approves Bausch + Lomb and Novaliq's Miebo for Dry Eye Treatment
May 22, 2023
Toxic Truth: 'Forever Chemicals' in Contact Lenses Linked to Cancer

Discover how 'forever chemicals' lurking in your contact lenses could be linked to cancer risks.

Toxic Truth: 'Forever Chemicals' in Contact Lenses Linked to Cancer
May 17, 2023
FDA Accepts Application for Genentech’s Vabysmo for Retinal Vein Occlusion

Genentech announced that the FDA has accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

FDA Accepts Application for Genentech’s Vabysmo for Retinal Vein Occlusion
May 10, 2023
Researchers Uncover Promising Path to Vision Restoration

Researchers at the Université de Montréal have made a groundbreaking discovery that offers new hope for restoring vision in patients with degenerative retinal disease.

Researchers Uncover Promising Path to Vision Restoration
May 08, 2023
FDA Approves Eyenovia’s Mydcombi, First Ophthalmic Spray for Mydriasis

Eyenovia Inc. announced that the FDA has approved Mydcombi, a groundbreaking ophthalmic spray that induces mydriasis for diagnostic procedures and short-term pupil dilation.

FDA Approves Eyenovia’s Mydcombi, First Ophthalmic Spray for Mydriasis
May 08, 2023
More